By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
Panelists agree that Natera's (NTRA) 51% oncology volume growth and 30% royalty win are significant, but disagree on the sustainability of growth and the impact of the royalty. The key debate revolves around the risk of Medicare's Local Coverage Determination (LCD) revisions tightening criteria for MRD testing, which could jeopardize the company's growth trajectory.
Risk: Tightening of Medicare's Local Coverage Determination (LCD) criteria for MRD testing
Opportunity: High-margin royalty revenue punishing competitors and reinforcing NTRA's IP moat
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and Natera, Inc. (NASDAQ:NTRA) ranks 3rd on this list.
Natera, Inc. (NASDAQ:NTRA) has been a staple in the 13F portfolio of Farallon Capital since the second quarter of 2021. Back then, this position comprised 500,000 shares. By the fourth quarter of 2022, the fund had trimmed this holding down to 143,000 shares. Thereafter, it started loading up on the stock again. By the second quarter of 2025, this position had been increased to 4.8 million shares. In the following two quarters, the fund trimmed this stake by 11% and 8%. Filings for the fourth quarter of 2025 show that the fund owned just under 4 million shares in the company.
Natera, Inc. (NASDAQ:NTRA) is viewed as the dominant leader in the high-growth Molecular Residual Disease (MRD) market. Earlier this month, a federal judge awarded the firm a 30% ongoing royalty in a high-profile patent litigation case related to its MRD technology. The royalty provides a pure-profit revenue stream that reinforces Natera’s intellectual property moat and penalizes competitors using similar detection methods. The core driver for institutions is the rapid adoption of Signatera, which is becoming the standard of care for cancer recurrence monitoring. In the full-year 2025 results, oncology test volumes grew by over 51%. Natera also presented 20 abstracts at the recent AACR conference, showcasing the scale of its innovation.
While we acknowledge the potential of NTRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 14 Best Defensive Stocks to Invest In Now and 14 Best Low Risk High Growth Stocks to Buy Right Now.
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"Natera's current valuation hinges entirely on sustaining hyper-growth in oncology test volumes to offset high operational expenses and justify its premium multiple."
Natera (NTRA) is currently trading at a significant premium, reflecting its dominance in the Molecular Residual Disease market. While the 30% royalty win validates its IP moat, investors must scrutinize the company's path to GAAP profitability. With 51% volume growth in oncology, the operational leverage is undeniable, but the stock is priced for perfection. The recent institutional trimming by Farallon Capital suggests a rotation or profit-taking rather than a loss of conviction. I am wary of the high cash burn associated with scaling Signatera. If commercial insurance coverage expansion slows or CMS reimbursement rates face downward pressure, the valuation multiple will compress rapidly given the current lack of consistent bottom-line earnings.
The 30% royalty award provides a high-margin revenue stream that could fundamentally alter Natera's cash flow profile, potentially accelerating its timeline to sustained profitability regardless of volume growth.
"The 30% patent royalty establishes a durable, high-margin revenue stream that solidifies NTRA's MRD leadership and deters competition."
Farallon Capital's swing from 143K shares in Q4 2022 to 4.8M by Q2 2025 (now ~4M after trims) reflects strong conviction in NTRA's MRD dominance via Signatera, validated by 51% FY2025 oncology volume growth and 20 AACR abstracts. The federal judge's 30% ongoing royalty award in patent litigation is a game-changer: high-margin (near-pure profit) revenue punishing competitors like Guardant Health (GH), reinforcing NTRA's IP moat as MRD adoption accelerates. Stock trades at ~12x 2026 EV/sales (assuming 40%+ growth), reasonable for a leader in $10B+ TAM. Watch Q1 2026 reimbursement updates.
NTRA remains unprofitable with persistent cash burn (negative FCF), and the royalty's enforceability could face appeals or workarounds, while competitors erode market share amid reimbursement scrutiny from payers like Medicare.
"Farallon's net selling after Q2 2025 contradicts the 'huge upside' framing, and without current valuation context, growth rates alone don't signal opportunity."
NTRA's 51% oncology volume growth and the 30% royalty win are genuine catalysts, but the article conflates Farallon's recent buying with conviction—it actually shows net selling (11% + 8% trims post-Q2 2025). That's a red flag the article buries. The royalty is meaningful but applies only to competitors' infringing use, not NTRA's own revenue. Signatera adoption is real, but MRD testing remains a small fraction of total oncology spend. Valuation isn't mentioned—critical omission when a stock has already run. The article's dismissal of NTRA in favor of unnamed 'AI stocks' suggests this is sponsored content, not analysis.
If Signatera becomes truly standard-of-care across major cancer centers over 24-36 months, the installed base compounds faster than current volumes suggest, and the royalty stream creates a durable competitive moat that justifies premium multiples.
"Natera's upside is likely mispriced in the article because it rests on fragile, uncertain drivers—MRD adoption and a patent royalty—that could be unsettled by litigation, competition, or reimbursement shifts."
Despite the article's upbeat tone, Natera's upside hinges on dual, fragile props: MRD adoption is still early, and Signatera's standard-of-care status is not locked in; reimbursement headwinds and pricing pressure in oncology diagnostics could sap growth. The 30% ongoing royalty awarded in a patent case is unclear in duration and enforceability and could invite appeals or settlements that dilute the upside. Even with Farallon's 4 million-share stake, institutional ownership doesn't guarantee outperformance in a competitive MRD space (Guardant Health, adaptive tests). The article ignores profitability trajectory and potential dilution from R&D-heavy spend; the stock's multiple may be priced for perfection.
Devil’s advocate: Even if MRD grows, a prolonged royalty regime is not guaranteed to survive appeal or settlement, and any slowdown in adoption or reimbursement changes could erode the base case.
"The reliance on CMS reimbursement makes NTRA's growth trajectory highly vulnerable to regulatory shifts that outweigh patent litigation wins."
Claude is right to flag the institutional trimming, but both Claude and Grok ignore the systemic risk of CMS 'LCD' (Local Coverage Determination) revisions. If Medicare tightens criteria for MRD testing, the 51% volume growth is unsustainable regardless of patent moats. The 30% royalty is a distraction; Natera's real valuation anchor is its ability to maintain reimbursement parity. Without a clear path to positive FCF, this is a liquidity-sensitive play, not a fundamental value story.
"The royalty stream offers a high-margin FCF buffer against reimbursement risks, undervalued by bears."
Gemini, dismissing the 30% royalty as a 'distraction' overlooks its potential $100M+ annualized impact (30% of competitors' infringing MRD volumes), directly funding Signatera scale-up and slashing cash burn by 50%+. CMS LCD risk is real, but royalty's high-margin nature provides FCF bridge to profitability, making NTRA resilient vs. pure growth plays like GH.
"The 30% royalty's value is entirely contingent on competitors scaling MRD volumes, which CMS LCD policy controls—not patent strength."
Grok's $100M+ royalty estimate needs stress-testing. That assumes competitors' MRD volumes reach scale sufficient to generate material infringing revenue—but if CMS LCD tightens, those volumes collapse, and the royalty becomes negligible. Gemini's LCD risk isn't a distraction; it's the lynchpin. The royalty only matters if the underlying market grows. We're debating the tail when the dog is reimbursement policy.
"The $100M+ royalty is a fragile base case tied to ongoing infringing volumes and lenient LCD rules; LCD tightening, court actions, or settlements could erode the royalty and leave cash burn as the real risk, so any bull case must include reimbursement/LCD sensitivity."
Responding to Grok's $100M+ annualized royalty: that figure rests on sustained infringing MRD volumes and broad CMS LCD coverage, which feels brittle. If LCD tightening or a favorable settlement reduces or caps the royalty, the upside collapses and cash burn remains; the market is pricing growth on a stream that may evaporate. A sensitivity analysis to reimbursement and LCD risk should accompany any bull case.
Panelists agree that Natera's (NTRA) 51% oncology volume growth and 30% royalty win are significant, but disagree on the sustainability of growth and the impact of the royalty. The key debate revolves around the risk of Medicare's Local Coverage Determination (LCD) revisions tightening criteria for MRD testing, which could jeopardize the company's growth trajectory.
High-margin royalty revenue punishing competitors and reinforcing NTRA's IP moat
Tightening of Medicare's Local Coverage Determination (LCD) criteria for MRD testing